Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Blood (2024) 143 (22): 2284–2299.

https://doi.org/10.1182/blood.2023021640

Published: 2024

Includes: Supplemental data

Journal Articles

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Lina Kolloch, Philipp Berning, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2023) 142 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2023-180078

Published: 2023

Journal Articles

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Julian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, Lina Kolloch, Philipp Berning, Simon Call, Matthias Floeth, Julia Marx, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2023) 142 (Supplement 1): 4911.

https://doi.org/10.1182/blood-2023-180723

Published: 2023

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Matthias Floeth, Elena Beckmann, Christian Reicherts, Julia Marx, Simon Call, Inna Shaforostova, Eva Eßeling, Jorn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes

Blood (2022) 140 (Supplement 1): 7587–7588.

https://doi.org/10.1182/blood-2022-165424

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Blood (2021) 138 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2021-145859

Published: 2021

Journal Articles

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Blood (2021) 138 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2021-145917

Published: 2021

Journal Articles

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Daniela V. Wenge, Klaus Wethmar, Corinna Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf M. Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brüggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes

Blood (2021) 138 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2021-146459

Published: 2021

Journal Articles

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Christoph Röllig, Christoph Schliemann, Jan-Henrik Mikesch, Lars Fransecky, Claudia D. Baldus, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Sebastian Scholl, Ulf Schnetzke, Kerstin Schäfer-Eckart, Knut Wendelin, Martin Wermke, Manja Reimann, Frank Fiebig, Theresa Kretschmann, Friedrich Stoelzel, Nael Alakel, Martin Bornhäuser

Blood (2021) 138 (Supplement 1): 2324.

https://doi.org/10.1182/blood-2021-150069

Published: 2021

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-138427

Published: 2020

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

Georg Evers, MD, Dietrich W. Beelen, Jan Braess, MD, Cristina Sauerland, Hans-Jochem Kolb, MD, Albrecht Reichle, MD, Ernst Holler, MD, Rainer Schwerdtfeger, MD, Renate Arnold, MD, Christoph Scheid, MD, Utz Krug, MD, Carsten Müller-Tidow, MD, Christoph Schliemann, MD, Jan-Henrik Mikesch, MD, Georg Lenz, Bernhard J. Wörmann, MD, Wolfgang Hiddemann, Wolfgang E. Berdel, MD, Matthias Stelljes, MD

Blood (2018) 132 (Supplement 1): 4649.

https://doi.org/10.1182/blood-2018-99-116964

Published: 2018

Journal Articles

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Christoph Groth, MD, Nina Kristin Steckel, MD, Jan-Henrik Mikesch, Rudolf Trenschel, MD, Hellmut Dietmar Ottinger, MD PhD, Carsten Müller-Tidow, Christoph Schliemann, Christian Reicherts, Eva Schmidt, Wolfgang E. Berdel, Georg Lenz, Markus Ditschkowski, Dietrich W Beelen, MD PhD, Matthias Stelljes, MD

Blood (2017) 130 (Supplement 1): 3205.

https://doi.org/10.1182/blood.V130.Suppl_1.3205.3205

Published: 2017

Journal Articles

Aldehyde Dehydrogenase 2 ( ALDH2 ) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia

Linus Angenendt, Eike Bormann, Jan-Henrik Mikesch, Tobias Herold, Klaus H. Metzeler, MD, Stefan K. Bohlander, MD, Dennis Görlich, Maria Francisca Arteaga, Bernhard J. Wörmann, Georg Lenz, Wolfgang Hiddemann, Karsten Spiekermann, Utz Krug, Christina Sauerland, Wolfgang E. Berdel, Christoph Schliemann

Blood (2017) 130 (Supplement 1): 1386.

https://doi.org/10.1182/blood.V130.Suppl_1.1386.1386

Published: 2017

Journal Articles

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Jan-Henrik Mikesch, MD, Christina Sauerland, Dipl.-Math, Tobias Herold, MD, Dennis Görlich, Eike Bormann, Wolfgang Hartmann, MD, Christoph Schliemann, MD, Bernhard J Wörmann, MD, Wolfgang Hiddemann, Karsten Spiekermann, MD, Matthias Stelljes, Utz Krug, MD, Carsten Muller-Tidow, MD, Thomas Büchner, MD, Wolfgang E Berdel, MD, Maria Francisca Arteaga, PhD

Blood (2016) 128 (22): 2840.

https://doi.org/10.1182/blood.V128.22.2840.2840

Published: 2016

NARROW

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1)

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Aldehyde Dehydrogenase 2 ( ALDH2 ) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia

High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only